Elevance Health stock gains as FY 2026 EPS guidance trails consensus

Elevance Health Inc. stock (ISIN US2855211023) traded at USD 410.71 on the New York Stock Exchange as of September 18, 2026, corresponding to a market capitalization of USD 89.07 billion and underscoring the insurer’s solid position in the managed care space.

FY 2026 guidance slightly under consensus

The current catalyst for Elevance Health stock is fresh earnings guidance for fiscal year 2026, which investors received in mid-September 2026. As MarketBeat reported on September 19, 2026, Elevance Health has issued earnings per share guidance of USD 27.00 for fiscal 2026, which is modestly below the analyst consensus estimate of USD 27.16 and thus implies a gap of USD 0.16 per share that the market now has to assess in light of recent profit trends.

According to the same overview by MarketBeat, analysts nonetheless maintain a generally positive stance on Elevance Health, assigning the stock a consensus rating of Moderate Buy and an average 12 month price target of USD 440.90. At a recent trading level around USD 410.71 as of September 18, 2026, this target implies potential upside of about USD 30.19 per share, or roughly 7.4 percent, which helps explain why the shares have remained firm even though the EPS guidance comes in slightly under the prior consensus.

Stock trades in upper part of 52-week range

The price level itself is supported by a robust medium term performance picture. In a recent profile of Elevance Health, Ad-hoc-news summarized that the stock has traded over the past 12 months between a low of USD 274.84 and a high of USD 436.24, placing the current area near USD 410 clearly above the low and moderately below the high. With the recent New York closing price of USD 410.71 on September 18, 2026, Elevance Health stands about USD 135.87 above its 12 month low and USD 25.53 below its 12 month high, situating the stock in the upper portion of its recent range.

Daily trading dynamics also show a lively order book. Per detailed trading data cited by Ad-hoc-news, Elevance Health shares changed hands on the New York Stock Exchange at around USD 414.26 intraday on September 18, 2026, with an intraday high of approximately USD 418.77 and an intraday low near USD 411.45, indicating a trading range of about USD 7.32 for that session. The closing price reported by MarketBeat at USD 410.71 on the same date therefore came in modestly below the intraday peak but clearly above the session low, a pattern that suggests investors locked in some gains while keeping the stock well supported.

Recent fundamentals and dividends in focus

Beyond the fresh 2026 EPS guidance, Elevance Health’s recent operating performance continues to underpin the valuation. In its latest available results for the most recent fiscal year, Elevance Health reported multi-billion dollar revenue and solid earnings, although the precise figures in that IR material lie outside the immediate seven day search window and therefore appear mainly as historical context rather than current fresh catalysts. The new EPS guidance of USD 27.00 for fiscal 2026, as highlighted by MarketBeat, can therefore be read as a continuation of strong profitability, albeit framed conservatively relative to consensus.

Shareholder returns also play a role in the investment case. Dividend data compiled by StockAnalysis show that Elevance Health declared a cash dividend of USD 1.720 per share with an ex-dividend date of September 10, 2026 and a scheduled payment date of September 25, 2026. On the morning of September 10, 2026, around 11:45 a.m. Eastern time, the stock was quoted at USD 411.95, up USD 15.05 or 3.79 percent in intraday trade, an indication that income-oriented investors are willing to support the stock as the dividend approaches.

Analyst stance and key risk considerations

The Moderate Buy consensus rating summarized by MarketBeat reflects that most covering analysts continue to expect Elevance Health to generate attractive returns, but it also signals that a meaningful minority rates the shares as Hold rather than Buy. In the same analysis, fifteen analysts were cited as assigning a Buy rating and eight as rating the stock Hold, which explains why the consensus price target of USD 440.90 sits only moderately above the current price instead of implying a more aggressive upside scenario.

For investors, the key risk around the latest guidance lies in the relatively tight spread between the company’s own EPS outlook and the consensus estimate. With guidance at USD 27.00 for fiscal 2026 compared to the USD 27.16 average analyst forecast, Elevance Health has effectively left itself limited room for disappointments without risking revisions, particularly if medical cost trends or regulatory changes weigh on margins. At the same time, the company’s ability to sustain dividends such as the USD 1.720 per share cash payout scheduled for late September 2026, as documented by StockAnalysis, suggests that balance sheet strength and cash generation remain important mitigating factors.

Stock price and trading venue

As of the latest completed trading day on September 18, 2026, Elevance Health stock closed at USD 410.71 on the New York Stock Exchange, down USD 3.55 or 0.86 percent from the prior close of USD 414.26, with an intraday high of USD 415.36 and a low of USD 406.38, and a reported volume of about 2.07 million shares, according to price data compiled by MarketBeat.

More news and analyses on Elevance Health stock